| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Impact Biomedical Inc.'s insiders have reduced their positions by a net 906 shares worth roughly $2K.
IBO sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 589.5K | $4.16M | - | |
| Dir | 250.2K | $162.6K | - | |
| CFO | 155.1K | $87.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Dss, Inc. | 10% Owner | Sell | 906 | $1.86 | $1,686.46 | -0.2% | - | - | |
| Mar 27, 2026 | MacKo Todd D | Chief Financial Officer | Sell | 45,000 | $0.56 | $25,330.38 | -22.5% | -17.2% | - | |
| Mar 23, 2026 | Grady Jason | Director | Sell | 50,000 | $0.65 | $32,505.00 | -16.7% | -17.7% | - | |
| May 27, 2025 | Dss, Inc. | 10% Owner | Sell | 161,000 | $0.55 | $88,005.58 | -22.8% | +8.7% | -8.2% | |
| May 27, 2025 | Dss, Inc. | 10% Owner | Sell | 161,000 | $0.55 | $88,005.58 | -100% | +8.7% | -8.2% | |
| Apr 4, 2025 | Dss, Inc. | 10% Owner | Sell | 890,800 | $0.95 | $845,012.88 | -84.7% | -32.2% | -33.5% | |
| Apr 3, 2025 | Chan Heng Fai Ambrose | Director | Sell | 351,555 | $0.50 | $174,019.73 | -100% | +45.3% | +27.4% | |
| Mar 27, 2025 | Dss, Inc. | 10% Owner | Sell | 605,620 | $3.22 | $1,950,928.47 | -36.5% | -57.8% | -74.8% | |
| Mar 20, 2025 | Dss, Inc. | 10% Owner | Sell | 53,300 | $4.68 | $249,408.40 | -100% | -79.2% | -62.5% | |
| Mar 20, 2025 | Dss, Inc. | 10% Owner | Buy | 200 | $1.55 | $310.00 | +0.4% | -79.2% | -62.5% |